Polyunsaturated fatty acid intake and risk of cardiovascular mortality in a low fish-consuming population: a prospective cohort analysis

Alice J. Owen*, Dianna J. Magliano*, Kerin O'Dea, Elizabeth L.M. Barr, Jonathan Shaw

**equal first authors*

Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia (AJO, DJM)

Baker IDI Heart & Diabetes Institute, Melbourne, Australia (DJM, ELMB, JS)

Sansom Institute for Health Research, University of South Australia, Australia (KO'D)

Corresponding author

Dr Alice Owen

Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia

6th Floor, The Alfred Centre

99 Commercial Rd, Melbourne, 3004, Australia

Email: alice.owen@monash.edu

Phone: +61 3 99030045

Fax: +61 3 99030556

Funding source: The AusDiab Study has been supported by numerous grants and in-kind support from a government and non-government sources. These are detailed in the acknowledgement section.

ABSTRACT

Purpose: The aim of this study was to examine the relationship between polyunsaturated fatty acid (PUFA) intake (n-6 and n-3) and mortality in a population-based sample with a low fish intake.

Methods: Cox-regression was used to examine the relationships between dietary PUFA intake and all-cause or CVD mortality in the Australian Diabetes, Obesity and Lifestyle study (AusDiab) cohort, a population of 11,247 Australians aged ≥25y recruited in 1999/2000 and followed until 2012. Demographic, lifestyle, and behavioural information was collected by questionnaire and fasting blood tests undertaken. Dietary intake was collected by a 121-item food frequency questionnaire. Vital status and causes of death were collected by death registry linkage.

Results: Those in the highest quintile of n-6 PUFA intake had lower risk of CVD mortality (HR: 0.57, 95%CI:0.38-0.86) after age and sex adjustment, but this failed to retain significance after further risk factor adjustment. Consumption of ≥ 1 serves/week of non-fried fish was associated with reduced risk of CVD mortality (HR:0.64, 95%CI:0.45-0.91, p=0.013) compared to those eating less than 1 serve/month, after sex and age adjustment, but did not retain significance after further adjustment. However long-chain n-3 intake was not associated with CVD mortality, and those in the highest quintile of n-3 intake had a higher risk of all-cause mortality.

Conclusions: These findings do not support previous suggestions that n-6 PUFA have adverse effects on CVD risk. Greater intake of non-fried fish was associated with lower risk of CVD mortality, but those with the highest total n-3 intake were at slightly increased risk of all-cause mortality.

KEYWORDS: diet, fatty acids, mortality, cardiovascular disease

INTRODUCTION

Since the relationship between dietary saturated fat and plasma cholesterol was discovered mid-last century, cardiovascular disease prevention strategies have included recommendations to replace animal-derived saturated fat with vegetable oils high in unsaturated fat [1]. Replacement of dietary saturated fat with polyunsaturated fat has been estimated to have the ability to reduce risk of coronary events and coronary death by 13% and 26% respectively [2].

Polyunsaturated fatty acids (PUFA) are classified as either n-3 (omega-3) or n-6 (omega-6). The major *in vivo* long chain n-6 PUFA, arachidonic acid, is the precursor of a number of biologically active metabolites including pro-inflammatory eicosanoids. n-3 PUFA of equivalent carbon length compete with n-6 PUFA forming eicosanoids and metabolites that have lower levels of pro-inflammatory activity, and are involved in resolution of inflammation [3]. As inflammation is thought to be involved in the aetiology of cardiovascular disease, there has been debate as to what effect n-6 PUFA themselves may have on cardiovascular risk, and whether any risk reduction seen with consumption of n-6 PUFA is driven largely by replacement of saturated fat.

A number of large-scale prospective studies have suggested that modest consumption of fish or very long chain n-3 PUFA (hereafter described as ‘n-3 PUFA’) is associated with reduced risk of cardiovascular disease (CVD) mortality, and in particular sudden cardiac death [4-6]. These findings are supported by the GISSI-Prevenzione randomised trial of fish oil in a post-myocardial infarction population which noted a 45% reduction in risk of sudden cardiac death [7]. Experimental evidence suggests that incorporation of the n-3 PUFA docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] into myocardial membranes drives the anti-arrhythmic effect [8], and this is independent of the background level of dietary n-6 PUFA [9]. However other studies have found no significant effect on CVD

mortality and these differences are reflected in disparate findings across a series of recent meta-analyses and systematic reviews [10-12].

Differences in background diet and both the amount and type of fish consumed may be important contributors to variability in the findings of observational studies examining the relationship between CVD mortality and n-3 PUFA. Despite the majority of the population living along the coastal fringe, Australians have previously been reported to have a relatively low intake of fish and very long chain n-3 PUFA (~180mg EPA+DHA/d) as compared to Japanese intakes which may be almost an order of magnitude higher (1600mg EPA+DHA/d) [13,14]. In contrast, n-6 PUFA intake in the Australian population has been reported to be relatively high (in the order of 5% of total energy) [15]. There is much debate regarding the ideal n-6 PUFA intake, with some suggesting the imbalance between n-6 and n-3 PUFA is a risk factor for chronic disease [16]. The evidence from prospective studies for this stance remains inconclusive [17-20]. The aim of the present study was to examine the relationship between PUFA intake and cardiovascular mortality in a population with a relatively low intake of fish.

METHODS

The Australian Diabetes, Obesity and Lifestyle study (AusDiab) is a national Australian prospective population-based cohort study of the prevalence and natural history of diabetes. Baseline measurements were collected during 1999–2000 on 11,247 non-institutionalised men and women aged ≥25 years. Detailed methods and response rates have been previously described [21]. Briefly, individuals were recruited from 42 randomly selected urban and non-urban census districts, six in each state and in the Northern Territory. Of the 17,129 eligible households, 20,347 individuals completed a household interview, and 11,247 (55.3%) had a biomedical examination, resulting in an overall response rate of 37%. Vital status and cause of death have been determined via linkage to the Australian National

Death Index (NDI). The study was approved by the Human Research Ethics Committees of the International Diabetes Institute, and Australian Institute of Health and Welfare, and all participants gave written informed consent.

Usual dietary intake was measured at baseline using a self-administered 121 item semi-quantitative food frequency questionnaire validated against weighed food records for macro- and micronutrients [22] and against plasma fatty acid biomarkers for fish intake [23]. Dietary data were analysed using the Australian NUTTAB 95 database, with fatty acid intakes estimated using the RMIT University fatty acid database, which contains fatty acid composition data for more than 1000 Australian foods [24].

For categorisation of fish intake, participants were classified into the following fish consumption groups: (1) <1 serving per month, (2) 1-3 times per month, (3) 1 time per week, (4) 2 times per week, (5) 3-4 times per week, (6) ≥5 times per week for non-fried fish, or total fish intake. For analyses examining 'adequacy' of intake, adequate intake was considered to be ≥ 500mg/day of very long chain n-3 fatty acids or 500g of fish/week as per National Heart Foundation of Australia recommendations [25]. Total n-6 PUFA intake was calculated as the sum of the major dietary n-6 fatty acid, linoleic acid (18:2n-6), plus the minor dietary n-6 components 20:2n-6 + 20:3n-6 + 20:4n-6 + 20:5n-6 + 22:4n-6. Total long chain n-3 was calculated as the sum of EPA (20:5n-3) + docosapentaenoic acid (22:5n-3) + DHA (22:6n-3).

Risk factors

Data on age, sex, history of CVD (angina, coronary heart disease or stroke) and smoking (never, ex- or current smoker) were collected by interview. Measurements included blood pressure, anthropometrics, fasting bloods and a 75g oral glucose tolerance test (OGTT). Plasma glucose, serum total cholesterol, triglycerides and high density lipoprotein (HDL-C) cholesterol were measured using an Olympus AU600 analyser (Olympus Optical, Tokyo,

Japan). All specimens were analysed at a central laboratory. Hypertension was defined a systolic or diastolic blood pressure of 140 mmHg or 90 mmHg, respectively or prescribed anti-hypertensive medication. Diabetes was defined according to WHO definition [26]. Total physical activity time (exercise) was calculated as the sum of the time spent performing moderate activity (including walking) plus double the time spent in vigorous activity [27].

Statistical methodology

To test differences in means and proportions for baseline characteristics Student's t-tests or chi-square analyses were used, respectively. The follow-up period for all-cause mortality was up to the date of death or 30 November 2012, whichever occurred first. As cause of death information was not available from the NDI for the same follow-up period as vital status data, the period of follow-up for CVD mortality was up to the date of death or 31 December 2009. Thirteen participants who died could not be matched to the NDI and were considered lost to follow-up and excluded and 31 deceased individuals had no cause of death available at the time of analysis.

The accuracy of the NDI for ascertainment of vital status and CVD deaths has been previously established [28]. People who were not matched to the NDI were assumed to be alive. Deaths were attributed to CVD if the underlying cause of death was coded I10-I25, I46.1, I48, I50-I99 or R96 according to the 2006 International Classification of Diseases 10th revision (ICD-10). Cox proportional hazards regression was used to estimate unadjusted and adjusted all-cause and CVD mortality hazard ratios (HR) and 95% confidence intervals (CI) of n-3 and n-6 intake. N-3 and n-6 intake were modelled in both quintiles, and trends over quintiles were tested by inclusion of quintile (categorical) variable as a continuous variable in the Cox model. Interactions for fish intake and n-3 and n-6 and sex for all-cause and CVD mortality were examined. Given the low statistical power inherent in interaction tests, interaction with a p value <0.2 were considered positive. Other variables known to be

confounding factors were included in the model. Multicollinearity between covariates was examined by calculating the mean and individual covariate variance inflation factors (VIF). Neither the individual or mean covariate VIFs were greater than 2 VIF for results presented herein.

For all-cause and CVD mortality we adjusted for age, sex, previous CVD (angina, coronary heart disease or stroke), smoking (current or ex-smokers), exercise, education, diabetes and total dietary energy (kJ). Neither waist circumference nor body mass index (BMI) contributed to the models and were thus not included. Similarly, cholesterol or total cholesterol:HDL ratio were not significant predictors of mortality and were not included in the final models. When we modelled the relationship between fish, PUFA and CVD mortality excluding those with CVD, similar patterns were observed compared to the full cohort but many estimates had lost statistical significance due to a loss of statistical power. We therefore retained original models using the entire population and adjusted for prior CVD. Non-linear effects were tested by fitting a quadratic terms of n-3 and or n-6 intake to fully adjusted models. The assumptions required for proportional hazards were met, and these were assessed with graphs of log-log plots of the relative hazards by time, and scaled Schoenfeld residuals. Analyses were conducted with SPSS version 18.0 (SPSS, Chicago, Illinois, USA) and Stata Statistical Software version 11.2 (StataCorp, College Station, Texas, USA). Values are given as Mean ± SD if not otherwise specified.

RESULTS

Study Population

The demographic and CVD risk characteristics of the AusDiab population are presented in Table 1. In brief, 55% were women and at baseline 15.8% were smokers and 7.4% had diabetes. Those who died in the follow-up period had significantly lower rates of schooling completion, and higher rates of diabetes and hypertension (Table 1).

Dietary n-3 PUFA Intake

The AusDiab population had a dietary intake of n-3 fatty acids approximately half that recommended for primary prevention of cardiovascular disease, as shown in Table 2. Median intake of long chain n-3 PUFA (EPA+DPA+DHA, hereafter referred to as 'n-3') in this cohort of Australian adults was 0.26g/d for women and 0.33g/d for men. Those in late middle age (55-64y) were more likely to be meeting recommended intake targets than younger age groups ($p<0.001$). Across all age ranges men had higher n-3 intakes than women ($p<0.001$) (Table 2), and men also had higher mean intakes of n-6 polyunsaturated fat (8.97g/d and 12.03g/d for women and men respectively, $p<0.001$) and higher total energy and fat intake (data not shown).

All-cause and CVD mortality

Over a median of 12.6 years, there were 1265 deaths (54% in men) representing a mortality rate of 9.3 per 1000 person years. For CVD mortality, there were 277 deaths (53% in men) over a median follow up of 9.7 years. The CVD mortality rate was 2.6 per 1000 person years.

Polyunsaturated fat intake and mortality

Those in the top quintile of n-6 intake were significantly protected from total and CVD mortality in age- and sex-adjusted models, with a significant dose response observed, *p* for trend =0.024, which did not retain significance following further adjustment for previous CVD, education, exercise, diabetes, total dietary energy and smoking (Table 3). N-3 intake was not an independent predictor of all-cause or CVD mortality in this population with relatively modest fish intake and there was no evidence of a relationship between n-3 intake and all-cause mortality and CVD mortality which deviated from linearity ($p>0.05$). The top quintile of n-3 intake was associated with a significantly increased risk of all-cause mortality, *p* for trend

188 =0.009 (Table 3, Model 2). Compared to those in the lowest quintile, those in the highest
189 quintile of n-3 intake were younger (51.0±13.7y vs 52.6±15.9y, *p=0.0002*), but had
190 significantly higher total energy intake (10229±4410 vs 6322±2247 kJ/d, *p<0.0001*),
191 saturated fat intake (46.3±23.8 vs 25.0±11.7 g/d, *p<0.0001*), and higher BMI (27.4±5.0 vs
192 26.9±5.3 kg/m^2, *p=0.0001*). We detected significant interactions for the relationship of n-3
193 intake (p=0.032) and n-6 intake (p=0.083) and sex and CVD mortality which met our criteria.
194 Figure 2 shows adjusted sex-specific HRs (95%CI) for the relationship between n-3 and n-6
195 intake in quintiles and all-cause and CVD mortality, and while not significant, the effects of n-
196 6 PUFA on CVD mortality showed divergent trends in men and women.
197
198 **Frequency of fish consumption and mortality**
199 In sex- and age adjusted models, frequency of intake of non-fried fish was associated with
200 lower risk of cardiovascular mortality (1-3 serves/month HR: 0.64 (95%CI:0.43-0.94), 1 serve
201 per week: 0.64 (0.45-0.91) and 2 or more serves per week: 0.63 (0.44-0.90), all p<0.05. But
202 as can been seen in Figure 1, after adjustment for sex, previous CVD, education, exercise,
203 diabetes, total energy intake and smoking the effect of non-fried fish consumption just failed
204 to reach significance [HR: 0.70 (95%CI:0.47-1.02)]. The addition of BMI or waist did not
205 materially alter the results. We detected significant interactions for the relationships of total
206 fish consumption and non-fried fish consumption and sex for all-cause mortality (p=0.021)
207 and CVD mortality (p=0.001) and table 3 gives the adjusted HR (95%CI) for non-fried and
208 total fish consumption by sex. As total fish consumption increased, the risk of all-cause
209 mortality increased, but these trends were not significant.
210
211
212 ## DISCUSSION
213 The present study found that n-6 PUFA intake was inversely associated with risk of all-cause
214 and cardiovascular mortality, although the significance of these associations was not

maintained after multivariate adjustment. The findings of this study make an important contribution to the ongoing debate surrounding PUFA intake and CVD risk, contrasting a recent finding from long-term follow up of another Australian cohort (the Sydney Diet Heart Study, a randomised dietary intervention trial) which found significantly higher rates of cardiovascular mortality in participants randomised to replacement of saturated fat with n-6 PUFA compared to those who maintained their usual diet [29]. Other prospective studies have found no significant association between n-6 PUFA and mortality [17,18], while the Nurses' Health Study is among the largest of the prospective studies which have found protective effects of n-6 PUFA on cardiovascular mortality [30]. The complexity of measuring and manipulating diet is a major limitation in long-term outcome studies, and this is reflected in contrasting conclusions from recent meta-analyses and reviews. Two recent meta-analyses highlight this equivocacy, one meta-analysis of randomised controlled trials concluded that diets high in n-6 PUFA might in fact increase the risk of CHD and mortality [20], whereas another recent meta-analysis has including the Nurses' Health Study data has concluded that dietary linoleic acid (the major n-6 PUFA) was dose-dependently inversely associated with cardiovascular mortality [31]. The findings of the present study strengthen support for the American Heart Association review which suggested that high intakes of n-6 PUFA were safe or possibly even cardioprotective [32].

The mechanisms governing cardioprotective effects of n-6 PUFA remain to be fully established. Early studies highlighted the cholesterol-lowering effects of n-6 PUFA rich diets [33], while more recent studies have noted that increased linoleic acid (18:2 n-6) intake is associated with reduced levels of C-reactive protein [34], and lower blood pressure [35], although the findings of the current study do not suggest that blood pressure was a driver of lower risk by quintile of n-6 intake. Conversely, carriers of risk alleles for hyperhomocysteinemia show increased levels of plasma homocysteine with increased n-6 PUFA intake [36], and linoleic acid intake was found to be associated with increased *ex vivo*

lipoprotein oxidisability [37]. Despite concerns surrounding pro-inflammatory and pro-atherogenic effects of n-6 PUFA which have been shown experimentally, to date there is little evidence of an increase in inflammatory-related cardiovascular disease with high n-6 PUFA intake [31,38]. While not significant, the findings of the present study suggested the possibility of sex differences in cardioprotection associated with n-6 PUFA. Sex was also identified as a significant source of heterogeneity in the meta-analysis of linoleic acid intake and coronary heart disease risk by Farvid and colleagues [30], but the nature and magnitude of any sex-differences in cardioprotection by n-6 PUFA remain to be clarified. There is some evidence to suggest that there may be sex-differences in incorporation of n-6 PUFA into platelet cell membrane phospholipids [39].

In the AusDiab cohort, non-fried fish consumption at a frequency of 2 or more times per week was associated with a significant reduction in CVD mortality risk. This effect was consistent, though more modest, than large cohort studies such as the US Physician's Health Study (RR 0.47, CI:0.23-0.98) [40] and the Cardiovascular Health Study (HR 0.53, CI:0.30-0.96) [4]. However those in the highest quintile of n-3 intake had a significantly increased risk of all-cause mortality, which raises a number of considerations. Fish and seafood are a major source long chain n-3 PUFA in the diet, although meat sources also make a significant contribution in the Australian diet [24], raising the possibility of confounding arising from high red meat intake [41]. The dietary questionnaire used in the AusDiab study was a 121-item food frequency questionnaire which had previously been validated for measurement of fish intake against plasma fatty acid biomarkers [22], but dietary intake is notoriously difficult to measure and this may contribute to an increase in error when examining relationships between health outcomes and nutrients found in small amounts (such as n-3 PUFA). Although not available in the present study, red blood cell fatty acid composition would be a more robust biomarker of usual long chain n-3 intake [42]. Another possibility is that there may be other nutrients or contaminants in fish influencing risk

of cardiovascular mortality. Fish is a good source of protein and selenium, but may also contain amounts of compounds with adverse effects, such as methylmercury, polychlorinated biphenols or dioxins, sometimes in large concentrations [43].

There remains considerable experimental evidence to support independent anti-arrhythmic and anti-inflammatory effects of n-3 [8,44], and the results of the GISSI-P randomised controlled trial of fish oil also strongly support the theory that EPA+DHA reduce risk of cardiovascular mortality [7]. Experimental evidence suggests that there is a threshold of incorporation into cellular membranes [9], and the body of clinical and human trial evidence suggests that the threshold for prevention of CVD mortality may be around 500mg EPA+DHA per day (equivalent to around 2-3 servings of fatty fish per week) [45]. The intake of long chain n-3 PUFA in the AusDiab cohort was slightly higher than that reported in the last published National survey of Australian dietary intake conducted in 1995 (which was in the order of~0.25g/d n-3 PUFA) [46], although intakes remained around half of that recommended by Australian and international bodies for primary prevention of CVD, and less than a third of that recommended for secondary CVD prevention.

The present study found a trend toward sex-differences in n-3 PUFA mediated protection from CVD mortality, with a non-significant n-3 mediated cardioprotection noted in men, but not women. Whether sex-differences exist in the effects of n-3 PUFA on CVD has yet to be clarified. Although some studies examining n-3 PUFA and CVD mortality have found no differences between men and women [47], others have noted sex-effects [48,49]. Mechanistically, it has been shown that sex-differences may exist in the anti-inflammatory effects of VLC n-3 PUFA, with EPA more effectively reducing platelet aggregation in males, whereas an anti-inflammatory effect of DHA is noted in females, but not males [50]. In addition, males and females may differ in metabolism of VLC n-3 PUFA post-ingestion [51].

The prospective study design is a strength of the present analyses, however there some limitations to be considered. The assumption was made that the dietary patterns measured represent usual and relatively stable dietary intake for the population under study, in addition use of dietary supplements was not assessed. While the assessment of diet using FFQs has limitations, in nutritional epidemiology FFQs remain widely used and accepted tools. One cannot discount the possibility of residual confounding from factors which were not measured in the present study, although attempts were made to include known plausible confounding factors.

In conclusion, this study suggests that increased dietary n-6 PUFA intake lowers risk of cardiovascular mortality. While the present study found intake of non-fried fish to be associated with a lower risk of cardiovascular mortality, cardiovascular benefits of n-3 PUFA were not evident.

Acknowledgment and Funding Sources

The AusDiab Study co-coordinated by the Baker IDI Heart and Diabetes Institute gratefully acknowledges the contribution of the study participants.

In addition AusDiab acknowledges the funding and in-kind support provided by: the Australian National Health and Medical Research Council (NHMRC grants 233200 and 1007544), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services – Tasmania, Department of Health – New South Wales, Department of Health – Western Australia, Department of

Health – South Australia, Department of Human Services – Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, sanofi-synthelabo, and the Victorian Government's OIS Program.

JS is supported by a National Health and Medical Research Council Fellowship.

Disclosures and conflicts: On behalf of all authors, the corresponding author states that there is no conflict of interest.

Author contributions

AJO and DJM designed research; DJM and AJO conducted research; DJM analyzed data; AJO, DJM, KO'D, ELMB and JS wrote and critically reviewed the paper; AJO had primary responsibility for final content. All authors read and approved the final manuscript.

REFERENCES

1. Brown WV, Ginsberg H, Karmally W (1984) Diet and the decrease of coronary heart disease. Am J Cardiol 54(5):27C-29C
2. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Balter K, Fraser GE, Goldbourt U, Hallmans G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A (2009) Major types of dietary fat and risk of coronary heart disease: A pooled analysis of 11 cohort studies. Am J Clin Nutr 89:1425-1432
3. Serhan CN, Yacoubian S, Yang R (2008) Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 3:279-312
4. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. N-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: The Cardiovascular Health Study (2003) Am J Clin Nut. 77:319-325
5. Mozaffarian D, Ascherio A, Hu FB, Stampfer MJ, Willett WC, Siscovick DS, Rimm EB (2005) Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 111:157-164
6. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS (2003) Cardiac benefits of fish consumption may depend on the type of fish meal consumed: The Cardiovascular Health Study. Circulation 107:1372-1377
7. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the Gissi-Prevenzione trial. Lancet 354:447-455
8. McLennan PL (2001) Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 36 Suppl:S111-114
9. Slee EL, McLennan PL, Owen AJ, Theiss ML (2010) Low dietary fish-oil threshold for myocardial membrane n-3 PUFA enrichment independent of n-6 PUFA intake in rats. J Lipid Res 51:1841-1848

10. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT (2008) Effect of fish oil on arrhythmias and mortality: Systematic review. BMJ 337:a2931

11. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G (2006) Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ 332:752-760

12. Marik PE, Varon J (2009) Omega-3 dietary supplements and the risk of cardiovascular events: A systematic review. Clin Cardiol 32:365-372

13. Ollis TE, Meyer BJ, Howe PR (1999) Australian food sources and intakes of omega-6 and omega-3 polyunsaturated fatty acids. Ann Nutr Metab 43:346-355

14. Sugano M (1996) Characteristics of fats in Japanese diets and current recommendations. Lipids 31 Suppl:S283-286

15. Flood VM, Webb KL, Rochtchina E, Kelly B, Mitchell P (2007) Fatty acid intakes and food sources in a population of older Australians. Asia Pac J Clin Nutr 16:322-330

16. Simopoulos AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 233:674-688

17. Esrey KL, Joseph L, Grover SA (1996) Relationship between dietary intake and coronary heart disease mortality: Lipid Research Clinics Prevalence Follow-up Study. J Clin Epidemiol 49:211-216

18. Pietinen P, Ascherio A, Korhonen P, Hartman AM, Willett WC, Albanes D, Virtamo J (1997) Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Epidemiol 145:876-887

19. Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC (1996) Dietary fat and risk of coronary heart disease in men: Cohort follow up study in the United States. BMJ 313:84-90

20. Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM (2010) N-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: A meta-analysis of randomised controlled trials. Br J Nutr 104:1586-1600

21. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M, Jolley D, McCarty DJ (2002) The Australian Diabetes, Obesity and Lifestyle Study (AUSDIAB)--methods and response rates. Diabetes Res Clin Pract 57:119-129

22. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G. The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. Aust N Z J Public Health. 2000;24(6):576-83.

23. Woods RK, Stoney RM, Ireland PD, Bailey MJ, Raven JM, Thien FC, Walters EH, Abramson MJ (2002) A valid food frequency questionnaire for measuring dietary fish intake. Asia Pac J Clin Nutr 11:56-61.

24. Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR (2003) Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 38:391-398

25. Colquhoun D, Ferriera-Jardim A, Udell T, Eden B (2008) Fish, fish oils, n-3 fatty acids and cardiovascular disease. National Heart Foundation of Australia Position Statement. Accessed 19 September 2012: http://www.heartfoundation.org.au/SiteCollectionDocuments/Fish-FishOils-position-statement.pdf

26. World Health Organization Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes

Mellitus. Geneva, Switzerland, Department of Noncommunicable Disease Surveillance (2009)

27. Australian Institute of Health and Welfare (2003) The Active Australia Survey. A guide and manual for implementation, analysis and reporting. Australian Government, Canberra.

28. Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, Barr EL, Zimmet PZ, Peeters A (2008) Lifetime risk and projected population prevalence of diabetes. Diabetologia 51:2179-2186

29. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR (2013) Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 346:e8707.

30. Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC (1997) Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 337(21):1491-9.

31. Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, Willett WC, Hu FB (2014) Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. Circulation 130(18):1568-78.

32. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, Engler MM, Engler MB, Sacks F (2009) Omega-6 fatty acids and risk for cardiovascular disease: A science advisory from the American Heart Association nutrition subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119:902-907

33. Mensink RP, Zock PL, Kester AD, Katan MB (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to hdl cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. Am J Clin Nutr 77:1146-1155

34. Enzenbach C, Kroger J, Zietemann V, Jansen EH, Fritsche A, Doring F, Boeing H, Schulze MB (2011) Erythrocyte membrane phospholipid polyunsaturated fatty acids are related to plasma c-reactive protein and adiponectin in middle-aged German women and men. Eur J Nutr 50(8):625-36

35. Miura K, Stamler J, Nakagawa H, Elliott P, Ueshima H, Chan Q, Brown IJ, Tzoulaki I, Saitoh S, Dyer AR, Daviglus ML, Kesteloot H, Okayama A, Curb JD, Rodriguez BL, Elmer PJ, Steffen LM, Robertson C, Zhao L (2008) Relationship of dietary linoleic acid to blood pressure. The International Study of Macro-Micronutrients and Blood Pressure study. Hypertension 52:408-414

36. Huang T, Tucker KL, Lee YC, Crott JW, Parnell LD, Shen J, Smith CE, Ordovas JM, Li D, Lai CQ (2011) Methylenetetrahydrofolate reductase variants associated with hypertension and cardiovascular disease interact with dietary polyunsaturated fatty acids to modulate plasma homocysteine in Puerto Rican adults. J Nutr 141:654-659

37. Louheranta AM, Porkkala-Sarataho EK, Nyyssonen MK, Salonen RM, Salonen JT (1996) Linoleic acid intake and susceptibility of very-low-density and low density lipoproteins to oxidation in men. Am J Clin Nutr 63:698-703

38. Gopinath B, Buyken AE, Flood VM, Empson M, Rochtchina E, Mitchell P (2011) Consumption of polyunsaturated fatty acids, fish, and nuts and risk of inflammatory disease mortality. Am J Clin Nutr 93:1073-1079

39. Geppert J, Min Y, Neville M, Lowy C, Ghebremeskel K (2010) Gender-specific fatty acid profiles in platelet phosphatidyl-choline and -ethanolamine. Prostaglandins Leukot Essent Fatty Acids 82(1):51-6.

40. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE (1998) Fish consumption and risk of sudden cardiac death. JAMA 279:23-28

41. Abete I, Romaguera D, Vieira AR, Lopez de Munain A, Norat T (2014) Association between total, processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis of cohort studies. Br J Nutr. 112(5):762-75.

42. Poppitt SD, Kilmartin P, Butler P, Keogh GF (2005) Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial. Lipids Health Dis 4:30

43. Mozaffarian D (2009) Fish, mercury, selenium and cardiovascular risk: Current evidence and unanswered questions. Int J Environ Res Public Health 6:1894-1916

44. Pepe S, McLennan PL (1996) Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 126:34-42

45. Mozaffarian D (2008) Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Clin Nutr 87:1991S-1996S

46. Howe P, Meyer B, Record S, Baghurst K (2006) Dietary intake of long-chain omega-3 polyunsaturated fatty acids: Contribution of meat sources. Nutrition 22:47-53

47. Wennberg M, Bergdahl IA, Hallmans G, Norberg M, Lundh T, Skerfving S, Stromberg U, Vessby B, Jansson JH (2011) Fish consumption and myocardial infarction: A second prospective biomarker study from northern Sweden. Am J Clin Nutr 93:27-36

48. Jarvinen R, Knekt P, Rissanen H, Reunanen A (2006) Intake of fish and long-chain n-3 fatty acids and the risk of coronary heart mortality in men and women. Br J Nutr 95:824-829

49. Lee SH, Shin MJ, Kim JS, Ko YG, Kang SM, Choi D, Jang Y, Chung N, Shim WH, Cho SY, Manabe I, Ha JW (2009) Blood eicosapentaenoic acid and docosahexaenoic acid as predictors of all-cause mortality in patients with acute

myocardial infarction--data from infarction prognosis study (IPS) registry. Circ J 73:2250-2257

50. Phang M, Sinclair AJ, Lincz LF, Garg ML (2012) Gender-specific inhibition of platelet aggregation following omega-3 fatty acid supplementation. Nutr Metab Cardiovasc Dis 22(2):109-14

51. Welch AA, Bingham SA, Ive J, Friesen MD, Wareham NJ, Riboli E, Khaw KT (2006) Dietary fish intake and plasma phospholipid n-3 polyunsaturated fatty acid concentrations in men and women in the European Prospective Investigation into Cancer-Norfolk United Kingdom cohort. Am J Clin Nutr 84:1330-1339

Table 1: Baseline characteristics of the AusDiab population according to vital status

	Alive	**All cause death**	**Alive**	**CVD death**
N	9982	1265	10930	277
Sex (Men)	43.7	54.23	44.5	57.0
Age [y] (SD)	49.2 (13.0)	70.1 (11.5)**	50.9 (14.1)	75.0(9.0)**
Education				
-Bachelor degree/post grad	18.1	7.5	17.2	4.8
-Associate Diploma	12.6	8.7**	12.3	7.8**
-Trade/technician	30.2	29.4	30.2	27.0
-Secondary school	39.2	54.5**	40.4	60.4**
Smoking				
-No smoking	56.0	47.1	55.3	45.9
-Ex smoker	28.1	37.7	28.9	42.5
-Current smoker	15.9	15.2*	15.8	11.6**
Diabetes	6.7	22.1	7.8	27.7 **
History of CVD	5.6	29.6**	7.5	41.2**
BMI [kg/m^2]	27.0 (5.0)	27.2(4.9)	27.0 (5.0)	27.0 (4.5)
Waist [cm]	90.4(13.9)	95.2 (13.7)**	90.8 (14.0)	95.7 (13.5)**
Hypertension	28.1	67.7 **	31.2	78.5**
Total cholesterol [mmol/l]	5.6 (1.1)	5.7 (1.1)*	5.7 (1.1)	5.7 (1.1)
HDL cholesterol [mmol/l]	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)	1.4 (0.4)
Triglyceride [mmol/l]	1.3 (0.9,1.9)	1.4 (1.2, 2.0)**	1.3 (0.9,1.9)	1.4 (1.0, 2.0)
VLC n-3 PUFA [g/d]	0.3 (0.2, 0.5)	0.3 (0.1, 0.5)*	0.3 (0.2, 0.5)	0.2 (0.1, 0.4)*
n-6 PUFA [g/d]	9.4 (6.3,13.5)	9.2 (6.1,12.6)	9.4 (6.3,13.4)	8.9 (5.6,11.9)
Saturated fat [g/d]	28.6 (20.1, 39.7)	25.5 (17.5, 35.5)**	28.3 (19.9, 39.4)	23.7 (17.3, 33.0)**

Data given as either mean (SD), median (25th, 75th interquartile range) or percentage of reporting population.

Differences between alive and deceased (all-cause or CVD-specific death) groups denoted by * p <0.05 or **p<0.001

Table 2: Median long chain omega-3 fatty acid intake in a cohort of Australian adults aged ≥25y

	N	DHA (g/d)	EPA(g/d)	DHA+EPA+DPA in g/d)
Men				
25-34y	560	0.20 (0.10, 0.35)	0.09 (0.04, 0.16)	0.34 (0.16, 0.57)
35-44y	1093	0.21 (0.13, 0.33)	0.09 (0.05, 0.16)	0.34 (0.21, 0.55)
45-54y	1345	0.21 (0.11, 0.32)	0.09 (0.05, 0.14)	0.34 (0.18, 0.54)
55-64y	928	0.20 (0.14, 0.36)	0.09 (0.05, 0.17)	0.32 (0.19, 0.60)
65-74y	731	0.18 (0.10, 0.28)	0.07 (0.04, 0.13)	0.28 (0.16, 0.47)
≥75y	362	0.15 (0.06, 0.27)	0.06 (0.03, 0.12)	0.25 (0.10, 0.45)
All men	*5019*	*0.20 (0.11, 0.33)*	*0.09 (0.04, 0.15)*	*0.32 (0.18, 0.55)*
Women				
25-34y	803	0.16 (0.09, 0.28)	0.07 (0.04, 0.13)	0.26 (0.14, 0.46)
35-44y	1465	0.16 (0.09, 0.26)	0.07 (0.04, 0.12)	0.26 (0.14, 0.43)
45-54y	1546	0.15 (0.09, 0.29)	0.07 (0.04, 0.13)	0.25 (0.15, 0.47)
55-64y	1096	0.18 (0.10, 0.30)	0.08 (0.04, 0.14)	0.29 (0.16, 0.49)
65-74y	837	0.14 (0.08, 0.25)	0.07 (0.03, 0.12)	0.24 (0.13, 0.43)
≥75y	451	0.13 (0.06, 0.23)	0.06 (0.03, 0.11)	0.22 (0.11, 0.35)
All women	*6198*	*0.16 (0.09, 0.27)*	*0.07 (0.04, 0.13)*	*0.25 (0.14, 0.45)*

Intake data given as weighted medians (25^{th}, 75^{th} interquartile range)

Table 3: Crude and adjusted hazard ratios for n-3 and n-6 PUFA consumption and all-cause and CVD mortality

	All-cause mortality				CVD mortality				
	Cases /Total (n/N)	Person years	Model 1	Model 2	Cases /Total (n/N)	Person years	Model 1	Model 2	Median PUFA intake (g)
Intake in quintiles									
N-3	350/2382	28479	1.00	1.00	90/2374	22334	1.00	1.00	0.09
2	214/2117	25862	0.82 (0.69-0.97)	0.98 (0.81-1.19)	47/2111	20167	0.75 (0.53-1.08)	0.92 (0.61-1.37)	0.19
3	237/2250	27358	0.90 (0.78-1.06)	1.07 (0.89-1.30)	58/2248	21382	0.93 (0.64-1.30)	1.04 (0.70-1.53)	0.29
4	213/2249	27440	0.82 (0.69-0.98)*	0.98 (0.80-1.20)	41/2240	21353	0.69 (0.48-1.00)	0.88 (0.57-1.36)	0.44
5	251/2249	27338	1.05 (0.89-1.24)	1.39 (1.13-1.70)*	41/2234	21262	0.79 (0.54-1.14)	1.00 (0.62-1.60)	0.81
N-6	286/2250	27148	1.00	1.00	70/2245	21259	1.00	1.00	4.12
2	247/2249	27279	0.92 (0.77-1.09)	1.04 (0.85-1.28)	54/2244	21291	0.84 (0.58-1.19)	1.12 (0.73-1.75)	6.91
3	268/2250	27171	0.94 (0.80-1.11)	1.13 (0.92-1.39)	60/2244	21222	0.85 (0.60-1.20)	1.22 (0.79-1.88)	9.39
4	249/2249	27261	0.89 (0.75-1.05)	1.04 (0.83-1.29)	58/2239	21254	0.85 (0.60-1.20)	1.14 (0.72-1.81)	12.45
5	215/2249	27618	0.82 (0.69-0.99)*	1.02 (0.79-1.32)	35/2235	21472	0.57 (0.38-0.86)**	0.88 (0.38-1.55)	17.68

Model 1 adjusted for age (timescale) and sex. Model 2 adjusted for age (timescale), sex, previous CVD, education, exercise, diabetes, total dietary energy and smoking.* Significant at $p<0.05$ **significant dose response, $p=0.024$

Table 4: Adjusted HR (95%CI) for total fish consumption and non-fried fish consumption and all-cause and CVD mortality by sex

	All-cause mortality		CVD mortality	
	Men	Women	Men	Women
Total fish consumption				
<1 serve per month	1.00	1.00	1.00	1.00
1-3 serves per month	0.73 (0.55-0.98)*	0.76 (0.54-1.08)	0.56 (0.31-1.02)	1.12 (0.53-2.33)
1 serve per week	0.81 (0.62-1.05)	0.84 (0.62-1.15)	0.77 (0.47-1.29)	0.88 (0.44-1.77)
2 or more times per week	0.96 (0.73-1.26)	0.97 (0.72-1.32)	0.69 (0.40-1.20)	0.85 (0.42-1.73)
Non-fried fish consumption				
<1 serve per month	1.00	1.00	1.00	1.00
1-3 serves per month	0.93 (0.76-1.27)	0.73 (0.54-0.98)	0.85 (0.51-1.41)	0.59 (0.31-1.31)
1 serve per week	0.98 (0.77-1.24)	0.78 (0.60-1.01)	0.77 (0.48-1.24)	0.60 (0.35-1.03)
2 or more times per week	1.11 (0.87-1.42)	0.91 (0.70-1.17)	0.72 (0.44-1.19)	0.60 (0.34-1.03)

Adjusted for age (timescale), previous CVD, education, exercise, diabetes, total dietary energy and smoking.

There were no significant dose responses.

Figure 1. CVD mortality by frequency of fish intake

A: Non fried fish consumption B: Total fish consumption



Data presented as adjusted HR ± 95% CI.

HRs are adjusted for age, sex, previous cardiovascular disease, smoking, total dietary energy, exercise and education.

Figure 2. CVD mortality by N3 and N6 intake in men and women



Data presented as adjusted HR ± 95% CI.

Model adjusted for age (time scale), previous cardiovascular disease, diabetes, smoking, total dietary energy, education, and alternately adjusted for n-3 and n-6 intake.